Cargando…

Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use

Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadonosono, Tetsuya, Yimchuen, Wanaporn, Ota, Yumi, See, Kyra, Furuta, Tadaomi, Shiozawa, Tadashi, Kitazawa, Maika, Goto, Yu, Patil, Akash, Kuchimaru, Takahiro, Kizaka-Kondoh, Shinae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972867/
https://www.ncbi.nlm.nih.gov/pubmed/31964960
http://dx.doi.org/10.1038/s41598-020-57713-4
_version_ 1783489925215158272
author Kadonosono, Tetsuya
Yimchuen, Wanaporn
Ota, Yumi
See, Kyra
Furuta, Tadaomi
Shiozawa, Tadashi
Kitazawa, Maika
Goto, Yu
Patil, Akash
Kuchimaru, Takahiro
Kizaka-Kondoh, Shinae
author_facet Kadonosono, Tetsuya
Yimchuen, Wanaporn
Ota, Yumi
See, Kyra
Furuta, Tadaomi
Shiozawa, Tadashi
Kitazawa, Maika
Goto, Yu
Patil, Akash
Kuchimaru, Takahiro
Kizaka-Kondoh, Shinae
author_sort Kadonosono, Tetsuya
collection PubMed
description Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we present a method to create such proteins, named fluctuation-regulated affinity proteins (FLAPs). Thirteen graft acceptor (GA) sites that efficiently immobilise the grafted peptide structure were initially selected from six small protein scaffolds by computational identification. Five CDR peptides extracted by binding energy calculations from mAbs against breast cancer marker human epithelial growth factor receptor type 2 (HER2) were then grafted to the selected scaffolds. The combination of five CDR peptides and 13 GA sites in six scaffolds revealed that three of the 65 combinations showed specific binding to HER2 with dissociation constants (K(D)) of 270–350 nM in biolayer interferometry and 24–65 nM in ELISA. The FLAPs specifically detected HER2-overexpressing cancer cells. Thus, the present strategy is a promising and practical method for developing small antibody mimetics.
format Online
Article
Text
id pubmed-6972867
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69728672020-01-27 Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use Kadonosono, Tetsuya Yimchuen, Wanaporn Ota, Yumi See, Kyra Furuta, Tadaomi Shiozawa, Tadashi Kitazawa, Maika Goto, Yu Patil, Akash Kuchimaru, Takahiro Kizaka-Kondoh, Shinae Sci Rep Article Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we present a method to create such proteins, named fluctuation-regulated affinity proteins (FLAPs). Thirteen graft acceptor (GA) sites that efficiently immobilise the grafted peptide structure were initially selected from six small protein scaffolds by computational identification. Five CDR peptides extracted by binding energy calculations from mAbs against breast cancer marker human epithelial growth factor receptor type 2 (HER2) were then grafted to the selected scaffolds. The combination of five CDR peptides and 13 GA sites in six scaffolds revealed that three of the 65 combinations showed specific binding to HER2 with dissociation constants (K(D)) of 270–350 nM in biolayer interferometry and 24–65 nM in ELISA. The FLAPs specifically detected HER2-overexpressing cancer cells. Thus, the present strategy is a promising and practical method for developing small antibody mimetics. Nature Publishing Group UK 2020-01-21 /pmc/articles/PMC6972867/ /pubmed/31964960 http://dx.doi.org/10.1038/s41598-020-57713-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kadonosono, Tetsuya
Yimchuen, Wanaporn
Ota, Yumi
See, Kyra
Furuta, Tadaomi
Shiozawa, Tadashi
Kitazawa, Maika
Goto, Yu
Patil, Akash
Kuchimaru, Takahiro
Kizaka-Kondoh, Shinae
Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title_full Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title_fullStr Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title_full_unstemmed Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title_short Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
title_sort design strategy to create antibody mimetics harbouring immobilised complementarity determining region peptides for practical use
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972867/
https://www.ncbi.nlm.nih.gov/pubmed/31964960
http://dx.doi.org/10.1038/s41598-020-57713-4
work_keys_str_mv AT kadonosonotetsuya designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT yimchuenwanaporn designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT otayumi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT seekyra designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT furutatadaomi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT shiozawatadashi designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT kitazawamaika designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT gotoyu designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT patilakash designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT kuchimarutakahiro designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse
AT kizakakondohshinae designstrategytocreateantibodymimeticsharbouringimmobilisedcomplementaritydeterminingregionpeptidesforpracticaluse